Safety and Efficacy of DIDALA Monotherapy in Patients With Type 2 Diabetes Compared With Metformin.
Study Details
Study Description
Brief Summary
This is an open-label, two-group parallel study, comparing before and after treatment within the same group and between the two groups. This study is designed to collect data on the safety and efficacy of a marketed pharmaceutical product (DIDALA) compared with Metformin. The efficacy data of DIDALA will be directly compared with Metformin 1000mg/day monotherapy in this study.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: DIDALA DIDALA is a herbal medicine, produced from dried mulberry leaves. The drug has been approved by the Drug Administration of Vietnam. |
Drug: DIDALA hard capsules
DIDALA is given orally with a dose of 2 capsules, 3 times per day for 12 weeks
|
| Active Comparator: METFORMIN
|
Drug: Metformin
Metformin 500mg, 1 tablet twice a day, immediately after breakfast and dinner for 12 weeks
|
Outcome Measures
Primary Outcome Measures
- Change from Baseline at Week 12 in Hemoglobin A1c (HbA1c) [12 weeks]
Hemoglobin A1c
Secondary Outcome Measures
- Change from Baseline at Week 12 in Fasting Plasma Glucose [12 weeks]
Fasting Plasma Glucose
- Safety assessments [12 weeks]
Safety will be assessed based on the frequency of occurrence of adverse events (AEs) of concern including hypoglycaemic events, clinically significant changes in laboratory parameters (complete blood count, blood biochemistry test), and vital signs during the study period.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
18 years or older at the time of enrollment in the study.
-
Diagnosed with type 2 diabetes according to the Guidelines for the diagnosis of type 2 diabetes of the Ministry of Health (2011).
-
Fasting blood glucose ≤ 10.0 mmol/L.
-
No previous treatment with metformin or other antidiabetic drugs.
-
Ability and willingness to provide written informed consent and comply with the protocol's requirements.
-
Subject who, in the judgment of the Investigator, is likely to be compliant or cooperative during the study.
Exclusion Criteria:
-
The patient has been diagnosed with diabetes and has been previously treated with metformin or other antidiabetic agents.
-
Patients with indications for insulin therapy or combination therapy of two or more drugs according to the guidelines for diagnosis and treatment of type 2 diabetes of the Ministry of Health.
-
Pregnancy or lactation.
-
Patients with contraindications to Metformin include severe liver and/or kidney disease, congestive heart failure, cardiovascular collapse, acute myocardial infarction, severe infection, and sepsis.
-
Patients with conditions and circumstances that, in the investigator's opinion, are difficult to ensure adherence to study protocol.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hanoi Hospital of Traditional Medical | Hanoi | Vietnam | ||
| 2 | National Hospital of Traditional Medicine | Hanoi | Vietnam |
Sponsors and Collaborators
- Centre of Clinical Pharmacology, Hanoi Medical University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- V5.0 08.08.2022